Humanity is aspiring to transcend old age and death. In the 21st century, this might no longer be an unattainable dream.
With everyday exposure to news media, movies, novels and theater, it is easy to assume that artificial intelligence (AI) will be able to provide all-powerful machinery capable of solving matters such as birth, aging, sickness or death — but how far has AI actually progressed in terms of medical science?
As top medical journals show, the progress made by AI goes no further than the ability to more meticulously analyze retinal changes as a result of diabetes in angiographic images; more precisely identify melanoma in dermoscopy images; find lymph node metastasis through analyzing histopathology images of breast cancer patients more accurately and faster than pathologists; forecast blood sugar levels by making calculations based on human genes and gastrointestinal microbiota; and assist oncologists’ decisionmaking by providing more informed and concise suggestions for cancer treatment, an AI technology provided by IBM’s Watson for Oncology.
The IBM Watson after its launch in 2016 received polarized opinions following its failure at the University of Texas’ MD Anderson Cancer Center, with some considering its AI capacity to be immature.
However, the higher the expectations, the greater the disappointment when the technology fails.
Just like the aforementioned advanced medical applications for AI technology, the IBM Watson for Oncology is by no means all-encompassing. It was not designed to diagnose cancers, but to target seven kinds of cancer and provide more in-depth and specific treatment advice. It also cannot give advice on surgery and radiation therapy, nor can it offer suggestions to patients with cancer recurrence or metastasis.
It might sound as if the IBM Watson is useless and not nearly as miraculous as the public believes it to be, but when it comes to treating people diagnosed with early stages of one of the seven targeted kinds of cancer, it provides detailed suggestions for medication and treatment, including chemotherapy, targeted therapy and immunotherapy.
Its suggestions are not only in accordance with the therapy already under way, but it also offers new directions and, in some cases, therapeutic opinions.
Within the scope of its database, IBM Watson is knowledgeable and it keeps “studying” new findings from journals to enhance the precision and subtlety of its analyses.
If the question is whether AI technology can replace an outstanding oncologist, the answer is “of course not.” However, if the question is changed to “Will AI under certain circumstances be able to assist oncologists by providing more precise therapeutic opinions for cancer patients?” then the answer is probably “yes.”
Every time a new technology emerges, public expectations rise too high on the assumption that it will solve all current difficulties. In particular, people find it hard to resist imaginative temptation when it comes to a sexy phrase such as “artificial intelligence.” These wild fantasies often lead to what is known as “technology hype.”
In terms of AI applications in medicine, moderate technology hype could encourage entrepreneurs to make venture investments and bring new capital into the field, thus encouraging the world’s top 10 companies to put a large amount of funds and talent into research. After all, finding the solution to issues related to birth, aging, sickness and death is humankind’s Holy Grail and a tremendously huge business that is growing 10 percent annually.
However, generating too much hype might lead to disappointments and the end of investment and research.
To AI researchers, this scenario sounds all too familiar. Since its emergence, AI has experienced at least two cold spells, both of which began when the technology was over-hyped and bestowed with too many unattainable goals. The Fifth-Generation Computer Systems initiated by Japan, for instance, disappeared quietly into thin air.
The question is whether there will be a third “cold spell” following the most recent emergence. Nevertheless, this possibility looks slim, as the causes of the two previous cold spells have been thoroughly analyzed and their lessons have been learned.
If concise development goals can be established, more rational expectations kept and an early harvest list for specific fields set up beforehand, current hardware processing speed and software maturity mean that the risk for a third cold spell is not great.
In other words, the public might finally be able to enjoy the fruits of AI technology.
Jack Li is dean of Taipei Medical University’s College of Medical Science and founder of the Center for Artificial Intelligence for Medical and Health Innovation.
Translated by Chang Ho-ming
Two sets of economic data released last week by the Directorate-General of Budget, Accounting and Statistics (DGBAS) have drawn mixed reactions from the public: One on the nation’s economic performance in the first quarter of the year and the other on Taiwan’s household wealth distribution in 2021. GDP growth for the first quarter was faster than expected, at 6.51 percent year-on-year, an acceleration from the previous quarter’s 4.93 percent and higher than the agency’s February estimate of 5.92 percent. It was also the highest growth since the second quarter of 2021, when the economy expanded 8.07 percent, DGBAS data showed. The growth
In the intricate ballet of geopolitics, names signify more than mere identification: They embody history, culture and sovereignty. The recent decision by China to refer to Arunachal Pradesh as “Tsang Nan” or South Tibet, and to rename Tibet as “Xizang,” is a strategic move that extends beyond cartography into the realm of diplomatic signaling. This op-ed explores the implications of these actions and India’s potential response. Names are potent symbols in international relations, encapsulating the essence of a nation’s stance on territorial disputes. China’s choice to rename regions within Indian territory is not merely a linguistic exercise, but a symbolic assertion
More than seven months into the armed conflict in Gaza, the International Court of Justice ordered Israel to take “immediate and effective measures” to protect Palestinians in Gaza from the risk of genocide following a case brought by South Africa regarding Israel’s breaches of the 1948 Genocide Convention. The international community, including Amnesty International, called for an immediate ceasefire by all parties to prevent further loss of civilian lives and to ensure access to life-saving aid. Several protests have been organized around the world, including at the University of California Los Angeles (UCLA) and many other universities in the US.
In the 2022 book Danger Zone: The Coming Conflict with China, academics Hal Brands and Michael Beckley warned, against conventional wisdom, that it was not a rising China that the US and its allies had to fear, but a declining China. This is because “peaking powers” — nations at the peak of their relative power and staring over the precipice of decline — are particularly dangerous, as they might believe they only have a narrow window of opportunity to grab what they can before decline sets in, they said. The tailwinds that propelled China’s spectacular economic rise over the past